Funding for High Throughput Screening
Preclinical Screening Platform for Pain (PSPP)
- Support: Within the NIH HEAL Initiative, NINDS created the Preclinical Screening Platform for Pain (PSPP) to identify and profile non-addictive therapeutics (small molecules, biologics, devices, or natural products) for acute and chronic pain.
- Participating Institutes: FIC, NCI, NCATS, NCCIH, NEI, NHLBI, NIA, NIAAA, NIBIB, NIDCR, NIDDK, NIDA, NINDS
- To apply: contact Program Director, Smriti Iyengar, smriti.iyengar@nih.gov
IGNITE: Assay Development and Neurotherapeutic Agent Identification
- Support: 3-year R61/R33 support assay development and neurotherapeutic agent identification
- Participating Institutes: NINDS, NCCIH
- To apply: PAR-21-124
Funding for Medicinal Chemistry (Hit-to-Lead)
Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes
- Support: 3-year R01s to improve probes for in vivo proof-of-concept studies
- Participating Institutes: NIMH, NEI, NIA, NIDA
- To apply: PAR-21-029
Funding for Preclinical Proof-of-Concept
Drug Discovery for Nervous System Disorders
- Support: Up to 5 years (R01) or 2 years (R21) of funding to support the discovery of novel compounds for the prevention and treatment of nervous system disorders.
- Participating Institutes: NIMH, NIA, NIAAA, NIDA
- To apply: PAR-19-147 (R01), PAR-19-146 (R21)
IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
- Support: 3-year R61/R33 support Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
- Participating Institute: NINDS
- To apply: PAR-21-122
Funding for Translational Model Development
IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
- Support: 3- year R61/R33 to support Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery
- Participating Institute: NINDS
- To apply: PAR-21-123
Funding for Preclinical/Clinical Development
National Cooperative Drug Discovery/Development Groups (NCDDG)
- Support: Up to 5 years of funding for multidisciplinary teams, Public Private Partnerships
- Participating Institutes: NIMH, NIAAA
- To apply: PAR-22-143 (U01), PAR-22-144 (U19)
Regulatory Affairs Assistance for Medications Development
- Support: Provides consultation and advice on regulatory requirements
- Participating Institute: NIDA
- To apply: Contact Marta DeSantis, Acting Branch Chief
Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)
- Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
- Participating Institute: NIAAA
- To apply: PAR-22-103 (UT1/UT2 - Clinical Trial Optional)
Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)
- Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
- Participating Institute: NIAAA
- To apply: PAR-22-102 (U43/U44 - Clinical Trial Optional)
Strategic Alliances for Medications Development to Treat Substance-Use Disorders
- Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
- Participating Institute: NIDA
- To apply: PAR-19-318 (R01)
Grand Opportunities in Medications Development for Substance-Use Disorders
- Support: Up to 3 years of funding, milestone-driven, up to $5M per year
- Participating Institute: NIDA
- To apply: PAR-19-327 (U01)
Alzheimer's Drug-Development Program
- Support: Up to 5 years of funding, milestone-driven, up to $1M per year
- Participating Institute: NIA
- To apply: PAR-22-047 (U01)
Services
Services for Pharmacology
Epilepsy Therapy Screening Program (ETSP)
- Support: Screens compounds in animal seizure models
- To apply: Contact Brian Klein, Ph.D.
Addiction Treatment Discovery Program (ATDP)
- Support: Screens compounds in animal models of addiction
- To apply: Contact David White, Ph.D., (301) 443-8889
NIMH Psychoactive Drug Screening Program (PDSP)
- Support: Screens novel psychoactive compounds for pharmacological and functional activity at cloned human or rodent CNS receptors, channels, and transporters.
- To apply: Contact Jamie Driscoll, (301) 443-5288
Services for Toxicology
Bridging Interventional Development Gaps (BrIDGs)
- Support: Provides synthesis, formulation, pharmacokinetic and toxicology expertise and resources to its collaborators and is open to any disease.
- To apply: See the National Center for Advancing Translational Sciences (NCATS) for more information.
NIMH Toxicological Evaluation of Novel Ligands Program
- Support: Provides toxicology, safety, in vitro ADME, and pharmacokinetic assessment of promising, target-selective compounds for use as imaging ligands and novel psychoactive drugs.
- To apply: Contact Jamie Driscoll, (301) 443-5288
NIDA Toxicology Program
- Support: Provides IND-directed toxicology services for substance abuse indications.
- To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475
Services for Chemistry
Bridging Interventional Development Gaps (BrIDGs)
- Support: Provides chemical synthesis services, open to any disease
- To apply: See National Center for Advancing Translational Sciences (NCATS) for more information
NIDA Drug Supply Program
- Support: Provides chemicals and research probes that are either unavailable, difficult to obtain, or very expensive to buy to researchers, including marijuana plant materials, cannabinoids, opioids, stimulants, sedatives, hypnotics, standardized research E-Cigarettes and nicotine research c, etc. Also provides analytical services for the analysis of researchers’ experimental samples.
- To apply: Contact: Richard Kline, Ph.D., (301) 443-5280
NIMH Chemical Synthesis and Drug Supply Program
- Support: Synthesizes and distributes novel research chemicals, psychoactive drugs, and compounds unavailable from commercial sources. Also supports radiosynthesis, medicinal chemistry, and GMP synthesis for clinical studies.
- To apply: Contact Jamie Driscoll, (301) 443-5288
NIDA Chemistry and Pharmaceutics Branch
- Support: Medicinal chemistry, analytical chemistry, metabolism, pharmacokinetics and pharmacodynamics, pharmacogenetics and pharmaceutics/formulation development aimed at the design, evaluation and development of medications for the treatment of drug addiction
- To apply: Contact Rik Klein, (301)-827-5243, rkline@nida.nih.gov
BPN Staff
Program Director
Charles Cywin, PhDHealth Program Specialist
Carolyn Bondar, PhDOperations Coordinator
Rakonda Medley, BS